Explain the DEFINITION Etiopathogenesis(CHART), Diagnosis(CLINICAL FEATURES, INVESTIGATION), Principles of management (NON PHARMACOLOGICAL & PHARMACOLOGICAL )and Ayurvedic perspective( SHODHAN & SAMANANA of Ashu Vrikka-nishkriyata (Acute Renal Failure) & Chirakaari vrikka-nishkriyata ( Chronic Renal Failure)

Reading File

Finding Sources

Reading File

Searching the Web

Ayurvedic perspective Ashu Vrikka Nishkriyata acute renal failure Shodhana Shamana treatment

Reading File

Reading Web Page

Ashu Vrikka Nishkriyata acute renal failure Chirakaari chronic renal failure Ayurvedic Shodhana Shamana etiopathogenesis

Finding Sources

Searching the Web

Vrikka Nishkriyata Ayurvedic concept ARF CRF Dosha Samprapti Shodhana Shamana herbs Punarnava Gokshura Varuna

Reading File

Searching the Web

Ashu Vrikka Nishkriyata Chirakaari Vrikka Nishkriyata Ayurvedic definition pathogenesis Dosha treatment Shodhana Basti

Reading File

Reading Web Page

Vrikka Nishkriyata acute chronic renal failure Ayurvedic Dosha Samprapti Shodhana Shamana Panchakarma treatment herbs

Loading Image

Ashu Vrikka-Nishkriyata (Acute Renal Failure / AKI) & Chirakaari Vrikka-Nishkriyata (Chronic Renal Failure / CKD)

PART I — ASHU VRIKKA-NISHKRIYATA (Acute Renal Failure / Acute Kidney Injury)

1. DEFINITION

Acute Kidney Injury (AKI) — formerly "Acute Renal Failure" — is a rapid decline in the kidney's ability to clear waste products and maintain fluid-electrolyte homeostasis, occurring over hours to days.

KDIGO 2012 Diagnostic Criteria (current gold standard)

Criterion	Threshold
Rise in serum creatinine	≥ 0.3 mg/dL within 48 hours OR
Rise in serum creatinine	≥ 1.5× baseline within prior 7 days OR
Urine output	< 0.5 mL/kg/h for ≥ 6 hours

STAGING (KDIGO)

Stage	Serum Creatinine	Urine Output
1	1.5–1.9× baseline or ≥0.3 mg/dL rise	<0.5 mL/kg/h × 6–12 h
2	2.0–2.9× baseline	<0.5 mL/kg/h × ≥12 h
3	≥3× baseline OR ≥4.0 mg/dL OR RRT initiated	<0.3 mL/kg/h × ≥24 h OR anuria ≥12 h

RIFLE Classification (older, still used):

Risk → Injury → Failure → Loss (complete loss >4 weeks) → ESKD

RIFLE (A) and KDIGO (B) staging — National Kidney Foundation Primer on Kidney Diseases, 8e

2. ETIOPATHOGENESIS — CHART

Etiological Classification

ACUTE KIDNEY INJURY (AKI)
│
├── PRE-RENAL (most common ~55–60%)
│   ├── Hypovolemia: hemorrhage, burns, vomiting, diarrhea, dehydration
│   ├── Low cardiac output: heart failure, cardiogenic shock, cardiac tamponade
│   ├── Systemic vasodilation: sepsis, anaphylaxis, hepatorenal syndrome
│   ├── Renal afferent arteriolar constriction: NSAIDs, contrast agents
│   └── Efferent arteriolar dilation: ACE inhibitors, ARBs
│
├── INTRA-RENAL / RENAL (~35–40%)
│   ├── Tubular (ATN — most common intrinsic cause)
│   │   ├── Ischemic ATN (prolonged prerenal → tubular necrosis)
│   │   └── Nephrotoxic ATN
│   │       ├── Exogenous: aminoglycosides, amphotericin B, contrast dye,
│   │       │             cisplatin, cyclosporine
│   │       └── Endogenous: myoglobin (rhabdomyolysis), hemoglobin (hemolysis),
│   │                        uric acid (tumor lysis), myeloma proteins
│   ├── Glomerular: rapidly progressive GN, SLE, vasculitis
│   ├── Interstitial: acute interstitial nephritis (drugs, infections)
│   └── Vascular: renal artery/vein thrombosis, malignant hypertension,
│                  thrombotic microangiopathy (HUS/TTP)
│
└── POST-RENAL / OBSTRUCTIVE (~5%)
    ├── Ureteral: calculi, strictures, retroperitoneal fibrosis
    ├── Bladder: BPH, neurogenic bladder, clot retention, bladder carcinoma
    └── Urethral: strictures, phimosis

Pathogenetic Mechanism of Ischemic ATN

↓ Renal Perfusion
       ↓
Tubular cell ischemia → ATP depletion
       ↓
↑ Intracellular Ca²⁺ + reactive oxygen species
       ↓
Cell swelling, brush border loss, cytoskeleton disruption
       ↓
Cell death (necrosis/apoptosis) → tubular obstruction by casts
       ↓
Backleak of glomerular filtrate → ↓ effective GFR
       ↓
Oliguria / Anuria → AKI

Key mediators: Loss of polarity, Na⁺-K⁺-ATPase mislocalization, tubuloglomerular feedback activation, afferent arteriolar vasoconstriction (endothelin, thromboxane A₂), neutrophil/macrophage infiltration.

3. DIAGNOSIS

A. CLINICAL FEATURES

Symptoms (develop as azotemia worsens):

Oliguria (<400 mL/day) or anuria (<100 mL/day)
Nausea, vomiting, anorexia
Fatigue, lethargy, confusion (uremic encephalopathy)
Asterixis, myoclonus (severe uremia)
Pericardial friction rub (uremic pericarditis)
Abnormal bleeding (platelet dysfunction)

Signs of volume overload:

Peripheral oedema
Raised JVP
Pulmonary oedema (dyspnoea, basal crepitations)
Hypertension

Signs pointing to etiology:

Hypotension + skin turgor ↓ → prerenal
Palpable bladder / suprapubic fullness → obstructive (post-renal)
Purpuric rash → vasculitis/HUS
Livedo reticularis → cholesterol emboli

Phases of AKI (particularly ATN):

Phase	Duration	Key Feature
Initiation	Hours–days	Injury occurring; creatinine rising
Oliguric	1–3 weeks (avg 10–14 days)	UO <400 mL/day; ↑ BUN, creatinine; hyperkalaemia, acidosis
Diuretic	Days–weeks	UO 3–5 L/day; risk of dehydration, hyponatraemia
Recovery	Weeks–months	GFR gradually returns; may be incomplete

B. INVESTIGATIONS

Urinalysis & Microscopy:

Finding	Suggests
Specific gravity >1.020; urine Na <20 mEq/L; FENa <1%	Prerenal
Granular "muddy brown" casts; renal tubular epithelial cells; urine Na >50 mEq/L; FENa >3%	ATN (intrinsic)
RBC casts, dysmorphic RBCs; proteinuria	Glomerulonephritis
WBC casts, eosinophiluria	Acute interstitial nephritis
No casts; dilute urine	Obstructive (post-renal)

FENa (Fractional Excretion of Sodium) = (Urine Na × Plasma Cr) / (Plasma Na × Urine Cr) × 100

Serum Biochemistry:

Serum creatinine & BUN (rising)
Electrolytes: Hyperkalaemia, Hyponatraemia, Hyperphosphataemia, Hypocalcaemia
Arterial blood gas: metabolic acidosis (↓ pH, ↓ HCO₃⁻, ↑ anion gap)
CBC: anaemia (dilutional), eosinophilia (AIN), thrombocytopenia (HUS/TTP)
Complement (C3/C4), ANA, ANCA, anti-GBM antibodies (if glomerular cause suspected)

Imaging:

Ultrasound kidneys: first-line — bilateral enlarged/normal kidneys (AKI); small kidneys (CKD); hydronephrosis (obstructive)
Doppler: renal artery/vein thrombosis
CT abdomen/pelvis (non-contrast): calculi, retroperitoneal pathology
Chest X-ray: pulmonary oedema

Renal Biopsy: Indicated when cause is unclear after initial workup, especially when glomerulonephritis or vasculitis is suspected.

Novel Biomarkers (early AKI detection):

NGAL (neutrophil gelatinase-associated lipocalin)
KIM-1 (kidney injury molecule-1)
Cystatin C
IL-18
TIMP-2 × IGFBP7 (NephroCheck®)

4. PRINCIPLES OF MANAGEMENT

A. NON-PHARMACOLOGICAL

Fluid management: Aggressive IV fluid resuscitation for hypovolaemia (isotonic saline or balanced crystalloids); avoid fluid overload. Fluid balance strictly monitored.
Dietary modification:
- Restrict protein (0.6–0.8 g/kg/day in non-dialysis AKI to reduce urea generation)
- Restrict potassium, phosphorus, sodium
- Adequate calories (25–35 kcal/kg/day) — enteral nutrition preferred
Avoidance of nephrotoxins: Withhold NSAIDs, aminoglycosides, contrast agents, ACE inhibitors/ARBs in the acute setting; dose-adjust all renally cleared drugs.
Monitoring: Strict intake/output, daily weights, cardiac monitoring (hyperkalaemia), blood pressure control.
Treat underlying cause: Relieve obstruction (catheterisation, nephrostomy), treat sepsis, remove nephrotoxic agents.
Renal Replacement Therapy (RRT) — non-pharmacological intervention:
- Indications (AEIOU): Acidosis, Electrolyte disturbance (refractory hyperkalaemia), Ingestion/toxin, Overload (pulmonary oedema), Uraemia (symptomatic — pericarditis, encephalopathy)
- Modalities: Intermittent Haemodialysis (IHD) or Continuous Renal Replacement Therapy (CRRT — preferred in haemodynamically unstable patients)

B. PHARMACOLOGICAL

Indication	Drug/Intervention
Prerenal hypotension	IV isotonic saline / balanced crystalloids; vasopressors (norepinephrine) in septic shock
Hyperkalaemia	IV calcium gluconate (membrane stabilisation); IV insulin + dextrose; sodium bicarbonate; calcium resonium/patiromer (exchange resins); dialysis for refractory cases
Metabolic acidosis	IV sodium bicarbonate (pH <7.1 or HCO₃⁻ <12 mEq/L)
Pulmonary oedema (volume overload)	IV furosemide (loop diuretic — converts oliguria, facilitates fluid management but does NOT improve outcome)
Sepsis-AKI	Broad-spectrum antibiotics; early goal-directed therapy
Contrast-induced AKI prophylaxis	IV N-acetylcysteine; adequate pre- and post-hydration; use iso-osmolar contrast
Hyperuricaemia (tumour lysis)	Rasburicase / allopurinol + aggressive hydration
Uremic bleeding	Desmopressin (DDAVP); dialysis
Anaemia	Erythropoiesis-stimulating agents (ESA) if prolonged; transfusion if severe

Note: Dopamine ("renal dose") is NOT recommended — no proven benefit in AKI.

PART II — CHIRAKAARI VRIKKA-NISHKRIYATA (Chronic Renal Failure / Chronic Kidney Disease)

1. DEFINITION

Chronic Kidney Disease (CKD) is defined as abnormalities of kidney structure or function, present for >3 months, with implications for health.

Diagnostic criteria (either one for >3 months):

GFR < 60 mL/min/1.73 m²
Markers of kidney damage: albuminuria (≥30 mg/24h), abnormal urinary sediment, electrolyte abnormalities due to tubular disorders, structural abnormality on imaging, history of kidney transplantation

KDIGO Staging of CKD

Stage	GFR (mL/min/1.73 m²)	Description
G1	≥90	Normal/High (with markers of damage)
G2	60–89	Mildly decreased
G3a	45–59	Mildly–moderately decreased
G3b	30–44	Moderately–severely decreased
G4	15–29	Severely decreased
G5	<15	Kidney failure (ESKD); dialysis/transplant

Albuminuria categories (A1: <30, A2: 30–300, A3: >300 mg/g) further risk-stratify.

2. ETIOPATHOGENESIS — CHART

Common Causes

CAUSES OF CKD (Global)
│
├── DIABETES MELLITUS (most common worldwide — ~40%)
│   └── Diabetic nephropathy: glomerulosclerosis (Kimmelstiel-Wilson lesion)
│       microalbuminuria → proteinuria → GFR decline
│
├── HYPERTENSION (~25–30%)
│   └── Hypertensive nephrosclerosis: afferent arteriolar thickening,
│       glomerular ischaemia, tubular atrophy, interstitial fibrosis
│
├── GLOMERULONEPHRITIS (~10–15%)
│   ├── IgA nephropathy, Focal segmental glomerulosclerosis (FSGS)
│   ├── Membranous nephropathy, Lupus nephritis
│   └── ANCA-associated vasculitis
│
├── HEREDITARY / GENETIC
│   ├── ADPKD (Autosomal Dominant Polycystic Kidney Disease)
│   └── Alport syndrome, Fabry disease
│
├── OBSTRUCTIVE NEPHROPATHY
│   └── Chronic BPH, renal calculi, posterior urethral valves
│
├── CHRONIC TUBULOINTERSTITIAL NEPHRITIS
│   └── Chronic analgesic use, heavy metals (lead, cadmium), sickle cell
│
└── RECURRENT AKI → progressive CKD

Pathogenetic Mechanism (Common Final Pathway)

Any Initiating Injury (DM, HTN, GN, etc.)
          ↓
Nephron loss → Compensatory hyperfiltration in remaining nephrons
          ↓
Intraglomerular hypertension → Glomerular hypertrophy
          ↓
Proteinuria → Tubulo-interstitial inflammation
          ↓
TGF-β activation → Fibroblast proliferation
          ↓
Glomerulosclerosis + Tubular atrophy + Interstitial fibrosis
          ↓
Further nephron loss → Self-perpetuating cycle
          ↓
End-Stage Kidney Disease (ESKD)

Key mediators of progression: Angiotensin II (intrarenal), TGF-β1, RAAS activation, oxidative stress, proteinuria itself (tubular toxicity), systemic and intraglomerular hypertension.

3. DIAGNOSIS

A. CLINICAL FEATURES

Early CKD (Stages 1–3): Usually asymptomatic; detected on screening (incidental lab findings).

Advanced CKD (Stages 4–5) — Uraemic Syndrome:

System	Manifestations
General	Fatigue, anorexia, nausea, weight loss, pruritis
CVS	Hypertension, LVH, pericarditis, accelerated atherosclerosis, arrhythmias
CNS	Lethargy, cognitive impairment, peripheral neuropathy, restless leg syndrome, uraemic encephalopathy
GIT	Anorexia, nausea, vomiting, peptic ulceration, GI bleeding (platelet dysfunction)
Haematological	Normochromic normocytic anaemia (↓ EPO), bleeding tendency, thrombocytopenia
Musculoskeletal	Renal osteodystrophy (osteoporosis, osteomalacia, osteitis fibrosa cystica), fractures, myopathy
Endocrine	Hyperparathyroidism (secondary → tertiary), hypogonadism, amenorrhoea, impotence, hypothyroidism
Fluid/Electrolyte	Oedema, hyperkalaemia, hyperphosphataemia, hypocalcaemia, hypermagnesaemia, metabolic acidosis
Skin	Pallor (anaemia), uraemic frost (severe), pruritus, hyperpigmentation
Immune	Immunosuppression → susceptibility to infections

B. INVESTIGATIONS

Blood Tests:

Serum creatinine + eGFR (CKD-EPI or MDRD equation)
BUN, electrolytes (K⁺ ↑, Na⁺ variable, phosphate ↑, calcium ↓)
Bicarbonate ↓ (metabolic acidosis)
CBC: normochromic normocytic anaemia; ↓ reticulocytes
Serum PTH ↑ (secondary hyperparathyroidism), Vitamin D ↓
Fasting lipids, blood glucose / HbA1c
Serum albumin (marker of nutritional status/inflammation)

Urine Tests:

Spot urine albumin:creatinine ratio (ACR) or protein:creatinine ratio (PCR) — performed twice
Urinalysis: proteinuria, haematuria, casts
24-hour urine collection (when needed for GFR estimation)

Imaging:

Renal ultrasound: bilateral small, echogenic kidneys (most CKD); loss of corticomedullary differentiation; exceptions: DM (kidneys may be normal/large early), ADPKD (markedly enlarged, cystic)
DMSA scan: differential renal function, scarring
CT KUB: structural anomalies, obstruction, calculi

Renal Biopsy: Indicated in CKD with suspected glomerular cause, unexplained rapid progression, or when nephrotic syndrome is present; generally avoided when kidneys are small.

ECG: Hyperkalaemic changes (peaked T waves, widened QRS, sine wave pattern).

4. PRINCIPLES OF MANAGEMENT

A. NON-PHARMACOLOGICAL

Dietary modification:
- Low protein diet (0.6–0.8 g/kg/day) — reduces uraemia and slows progression
- Sodium restriction (<2 g/day) — BP control, oedema
- Potassium restriction (if hyperkalaemic)
- Phosphate restriction (<800 mg/day); avoid phosphate-rich foods (dairy, nuts, processed food)
- Adequate caloric intake (35 kcal/kg/day)
- Fluid restriction (in advanced CKD)
Lifestyle modifications:
- Smoking cessation (independent risk factor for progression)
- Regular moderate exercise
- Weight reduction (BMI <25)
- Alcohol moderation
BP control target: <130/80 mmHg (or <125/75 if proteinuria >1 g/day)
Avoidance of nephrotoxins: NSAIDs, contrast dye, herbal nephrotoxins, aminoglycosides
Patient education & self-management: Home BP monitoring, understanding signs of decompensation, fluid balance logs
Renal Replacement Therapy (RRT) — when GFR <15 or symptomatic uraemia:
- Haemodialysis (HD): 3× weekly, 3–4 hours; requires arteriovenous fistula
- Peritoneal Dialysis (PD): CAPD or APD; home-based; better for residual renal function preservation
- Renal Transplantation: Treatment of choice for ESKD; best long-term outcomes

B. PHARMACOLOGICAL

Problem	Drug / Strategy
Slow progression	ACE inhibitors / ARBs — reduce intraglomerular pressure, reduce proteinuria (first-line in DM-CKD and proteinuric CKD)
	SGLT2 inhibitors (empagliflozin, dapagliflozin) — reduce CKD progression and cardiovascular events (now guideline-recommended)
	Finerenone (non-steroidal MRA) — reduce CKD progression in DM
Hypertension	ACE inhibitors/ARBs (first-line); CCBs, beta-blockers as add-on
Anaemia	Erythropoiesis-stimulating agents (ESA — darbepoetin, epoetin); IV iron (if ferritin <200 µg/L or TSAT <20%) — target Hb 10–12 g/dL
Hyperphosphataemia	Calcium carbonate (calcium-based binders); Sevelamer (non-calcium); lanthanum carbonate; iron-based binders
Secondary HPT	Calcitriol (activated Vit D) or analogues (paricalcitol); Cinacalcet (calcimimetic — for tertiary HPT)
Metabolic acidosis	Sodium bicarbonate supplementation (target HCO₃⁻ ≥22 mEq/L)
Hyperkalaemia	Dietary restriction; loop diuretics; sodium/potassium exchange resins (patiromer, sodium zirconium cyclosilicate)
Oedema / volume overload	Loop diuretics (furosemide — higher doses needed as GFR falls); thiazides lose efficacy when GFR <30
Dyslipidaemia	Statins (atorvastatin, rosuvastatin) — reduce CV events in CKD
Diabetes control	Metformin (discontinue if GFR <30); SGLT2 inhibitors (adjust for GFR); insulin; avoid nephrotoxic oral hypoglycaemics
Infections	Vaccinations: Influenza (annual), Pneumococcal, Hepatitis B
Renal bone disease	Phosphate binders + Vitamin D analogues + Cinacalcet; bisphosphonates (use with caution in CKD)

PART III — AYURVEDIC PERSPECTIVE

Conceptual Mapping

Modern Term	Ayurvedic Equivalent
Kidney	Vrikka (a pair; embryologically derived from Rakta + Meda dhatu)
Acute Renal Failure	Ashu Vrikka-Nishkriyata (sudden / rapid cessation of kidney function)
Chronic Renal Failure	Chirakaari Vrikka-Nishkriyata (prolonged, gradual decline of kidney function)
Urine formation channels	Mutravaha Srotas
Urinary bladder	Basti (also the main seat of Vata)
Waste filtration	Kleda-vahana (kleda = excess fluid/moist waste)

Dosha-Dushya Analysis

Pradhana Dosha: Tridosha derangement, with Vata-Kapha predominance (especially in CRF); Pitta involvement in inflammatory/haemorrhagic causes.

Dushya (affected tissues/channels):

Rakta dhatu (blood tissue) — kidney's embryological origin
Meda dhatu (fat/lipid tissue) — Vrikka moolasthana
Mutravaha Srotas — channels of urine formation/excretion

Srotodushti (channel pathology): Primarily Sanga (obstruction) → Vimargagamana (misdirection of flow)

ASHU VRIKKA-NISHKRIYATA — Etiopathogenesis (Samprapti)

NIDANA (Causative Factors):
├── Ahara: Ati-ruksha (excessively dry food), Kshara (alkaline/caustic substances),
│         Ati-lavana (excessive salt), Viruddha ahara, dehydrating foods
├── Vihara: Trauma, excessive exertion, haemorrhage, suppression of natural urges (vegadharana)
└── Vyadhi: Infections (jwara), toxins (visha), haemolysis, post-surgical states

                    ↓
      PURVARUPA (Prodromal signs):
      Reduced urine output, lower back discomfort, fatigue

                    ↓
      SAMPRAPTI (Pathogenesis):
      Nidana Sevana
            ↓
      Vata-Pitta vitiation
      (Vata: governs urine flow / filtration; Pitta: metabolic fire)
            ↓
      Mutravaha Srotas Dushti (obstruction/damage)
            ↓
      Kleda (fluid waste) fails to be eliminated
            ↓
      Toxin accumulation (Ama formation) → Srotosanga
            ↓
      Agnimandya (impaired metabolic fire) → further Ama
            ↓
      Rapid Vrikka Kshaya (acute kidney dysfunction)
            ↓
      RUPA (Manifestations):
      Anuria/Oliguria, Shotha (oedema), Aruchi, Chardi, Bhrama,
      Klama, Sandhi shoola (uremic musculoskeletal pain)

CHIRAKAARI VRIKKA-NISHKRIYATA — Etiopathogenesis (Samprapti)

NIDANA:
├── Ahara: Guru-Snigdha-Sheeta-Abhisyandi (heavy, oily, cold, congestive) foods
│         → Kapha/Meda vitiation; Ati-lavana-amla-teekshna → Rakta-Pitta vitiation
├── Vihara: Sedentary lifestyle, day-sleep (Divaswapna → Kapha accumulation)
├── Vyadhi: Madhumeha (diabetes), Raktachapa (hypertension), Mutrashmari (calculi),
│           repeated AKI episodes, Beejadushti (genetic factors / ADPKD)
└── Manasika: Chronic stress → Vata derangement

                    ↓
      SAMPRAPTI:
      Nidana Sevana
            ↓
      Tridosha vitiation (Vata-Kapha predominant)
            ↓
      Rakta + Meda Dushti (primary dhatu affected — kidney's origin)
            ↓
      Medovaha + Mutravaha Sroto Dushti (Srotosanga + Srotodushti)
            ↓
      Agnimandya → Ama Utpatti (toxic metabolic byproducts)
            ↓
      Progressive Vrikka Kshaya (nephron loss / fibrosis)
            ↓
      Kleda accumulation (uraemic toxins, fluid retention)
            ↓
      RUPA: Pandu (anaemia), Shopha (oedema), Aruchi, Chardi,
            Mootravaha srotas dushti (oliguria/polyuria), Sarvangavedana,
            Twaka rukshata (dry skin), Hrudroga (cardiovascular), Daurbalya
            ↓
      Yapya/Asadhya (incurable/palliable) stage = ESKD

AYURVEDIC TREATMENT PRINCIPLES

Chikitsa Sutra (Treatment Goals)

Break the Samprapti → Achieve: Ama pachana + Sroto shodhana + Rakta prasadana + Kleda-medososhana + Doshic balance + Rasayana chikitsa

SHODHANA CHIKITSA (Bio-Purification / Panchakarma)

Indicated when the patient has adequate bala (strength); best in early-to-moderate stages.

1. Purva Karma (Preparatory Procedures)

Procedure	Detail
Snehana (Internal/External Oleation)	Medicated ghee/oil (e.g., Mahatiktaka ghrita, Dhanwantaram taila) — liquefies and mobilises Ama
Swedana (Sudation)	Avgaha Sweda (medicated sitz bath with Punarnava kwatha, dashamoola) — particularly suited to renal conditions; opens Srotas, promotes elimination through skin

2. Pradhana Karma (Main Procedures)

Panchakarma	Relevance to Vrikka-Nishkriyata
Virechana (Purgation)	For Pitta-predominant/inflammatory AKI; eliminates Ama, Pitta; uses Trivrut leha, Eranda taila; clears Mutravaha srotas indirectly via Pakwashaya shodhana
Basti (Medicated Enema)	MOST IMPORTANT — Vata's primary seat is Pakwashaya (colon); Basti pacifies Vata, the dominant dosha in both AKI/CRF; achieves systemic Shodhana without over-taxing kidneys
→ Niruha Basti (Kashaya Basti)	Punarnava Kwatha Basti; Dashamoola Kwatha Basti — decoction enema for Srotoshodhana
→ Anuvasana Basti (Sneha Basti)	Dhanwantaram oil; Ksheerabala oil — nourishes, lubricates, Vata-shamaka
Abhyanga (Medicated Oil Massage)	Dhanwantaram taila, Ksheerabala taila — promotes circulation, Vata pacification
Virechana + Basti (Yoga Basti cycle)	8-day cycle: 3 Anuvasana + 5 Niruha Basti — standard protocol in CRF management

Note: Vamana (emesis) is generally contraindicated in severe renal failure with hypovolaemia. Raktamokshana (bloodletting — jalauka/leech therapy) may be considered in Pitta-dominant/inflammatory cases.

SHAMANA CHIKITSA (Palliative / Conservative Treatment)

Used alone in debilitated patients; used after Shodhana as maintenance.

Key Therapeutic Strategies

Goal	Intervention
Ama pachana (Digest toxins)	Ginger (Shunti), Pippali, Haritaki, Trikatu churna
Mutral (Diuretic)	Punarnava, Gokshura, Varuna (Crataeva nurvala), Pashanabheda (Bergenia ligulata)
Srotoshodhana (Channel cleansing)	Manjistha, Chandana, Ushira (Vetiver)
Rakta prasadana (Blood purification)	Manjistha, Neem, Guduchi (Tinospora cordifolia)
Vata-Kapha Shamana	Punarnava, Shilajatu, Gokshura
Anti-inflammatory / nephroprotective	Guduchi (Tinospora cordifolia), Amalaki, Bhumyamalaki (Phyllanthus niruri)
Rasayana (Regenerative/Tonic)	Shilajatu, Chyawanprash, Ashwagandha, Punarnava mandura (for anaemia)

Key Ayurvedic Formulations

Formulation	Composition / Use
Punarnavashtaka Kashaya	Punarnava, dashamoola, ginger etc. — diuretic, anti-oedematous, Vata-Kapha shamaka
Gokshuradi Guggulu	Gokshura, Guggulu, Trikatu — mutral, anti-inflammatory, breaks Srotosanga
Varuna / Varunadya Kashaya	Crataeva nurvala — mutra-shodaka (urine purifier), dissolves calculi
Chandraprabha Vati	Multi-herbal — urinary tonic, metabolic regulator
Punarnava Mandura	Punarnava + Mandura (iron) — anaemia of CKD (renal anaemia / Pandu)
Mutrakrichhantaka Rasa	Rasa preparation — acute urinary obstruction/AKI with dysuria
Shilajatu (Asphaltum)	Rasayana — improves glomerular function, anti-oxidant, adaptogen
Bhumyamalaki (Phyllanthus niruri)	Hepato-nephroprotective — reduces proteinuria, antiviral
Guduchi Satva	Tinospora cordifolia extract — immunomodulator, anti-uraemic

Specific Treatment of Ashu Vrikka-Nishkriyata (AKI)

Phase	Ayurvedic Approach
Acute phase (Initiation/Oliguric)	Shodhana deferred; focus on: Ama pachana (Ginger, Haritaki), Sroto unblocking (Punarnavashtaka), IV fluid equivalent = Yavagu (rice gruel), light easily digestible diet; Vastika dravyas (diuretics) cautiously
Diuretic phase	Rasayana + rehydration; Balya (strengthening) therapy begins
Recovery	Rasayana (Chyawanprash, Ashwagandha), dietary restoration, Yoga/Pranayama

Specific Treatment of Chirakaari Vrikka-Nishkriyata (CRF/CKD)

Stage	Ayurvedic Approach
Early (G1-G2)	Nidana Parivarjana (remove causative factors); Pathya Ahara-Vihara; Mutral + Rasayana; Shodhana (if bala adequate)
Moderate (G3)	Basti (Yoga basti), Virechana; Shamana — Punarnava, Gokshura, Guduchi, Chandraprabha; Manage Pandu with Punarnava Mandura
Advanced (G4-G5)	Primarily Shamana + Rasayana; Basti (Matra Basti with small quantities of medicated oil — safer); Ahara and Vihara adjustments; Integrate with dialysis if on RRT
ESKD	Palliative Ayurveda — symptom relief (pruritus: medicated oil massage; nausea: ginger; fatigue: Ashwagandha); supportive alongside RRT/transplant

Pathya (Recommended Diet & Lifestyle)

Light, warm, easily digestible food (Laghu, Ushna Ahara)
Yava (barley), Old rice (Purana shali), Moong dal
Bitter vegetables (karela/bitter gourd — Tikta rasa cleanses Rakta/Pitta)
Avoid: Excess salt (Lavana), sour (Amla), heavy (Guru), cold, processed, dairy (Abhisyandi)
Adequate hydration (unless oliguric)
Mild Yoga: Pranayama (Anulom-Vilom), Bhujangasana, Setu Bandhasana
Avoid: Divaswapna (day sleep), holding natural urges, excessive exertion

Summary Comparison Table

Feature	Ashu Vrikka-Nishkriyata (ARF/AKI)	Chirakaari Vrikka-Nishkriyata (CRF/CKD)
Onset	Sudden (hours–days)	Gradual (>3 months)
Reversibility	Potentially reversible	Usually irreversible; progressive
Kidney size (USG)	Normal to enlarged	Small, echogenic
Creatinine	Rapidly rising	Chronically elevated
Anaemia	Mild/absent (acute)	Prominent (↓ EPO)
Osteodystrophy	Absent	Present (secondary HPT)
Ayurvedic predominant dosha	Vata-Pitta	Vata-Kapha
Primary Shodhana	Basti (Niruha + Anuvasana)	Basti (Yoga Basti) + Virechana
Key herbs	Punarnava, Varuna, Gokshura	Punarnava, Gokshura, Guduchi, Shilajatu
Rasayana	Post-recovery phase	Central to long-term management
RRT equivalent	Acute Basti + Virechana (elimination)	Dialysis + Basti (maintenance)

Sources: Sabiston Textbook of Surgery 21e, National Kidney Foundation Primer on Kidney Diseases 8e, Brenner & Rector's The Kidney 2-Volume Set, KDIGO AKI Guidelines 2012; Ayurvedic content synthesized from IJCRT 2024 (Pathogenesis of CKD in Ayurveda), WJPLS 2025 (Vrikka Vikara management), DOAJ case reports on Shodhana-Shamana in CKD.

This is a shared conversation. Sign in to Orris to start your own chat.